OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS

Capital Raises

Past Charts

Debt Capital Raises

Debt Transaction Chart

Viridian publishes weekly data and analysis on debt capital raises in the Cannabis/CBD/Psychedelic industries. This data includes information about the company issuing debt (public/private, state/country location), deal size, deal structure, pricing, warrants, and credit data.

Week ended 05/31/2024

Debt Commentary

Viridian publishes weekly insights on debt capital raises in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful debt transactions of that week, and commentary on market conditions, debt deal structures, and lenders.

Week ended 05/31/2024

  • Debt accounted for 62% of trailing 8-week capital raises, roughly unchanged from last week. The ratio may go if companies are able to utilize favorable regulatory-induced stock price increases to complete equity issues.

 

  • The Week’s Debt Transactions
  • On May 23, 2024, MyMD Pharmaceuticals (MYMD: Nasdaq), a biotech company developing a clinical-stage syntheti
  • On May 29, 2024, IM Cannabis Corp. (IMCC: Nasdaq) (IMCC: CSE), a leading medical cannabis company with operations in Israel and Germany, closed a $1.53M private placement of Convertible Debentures.
    • The notes have a four-year maturity and carry no interest rate.
    • The notes are convertible at US$0.62 per share (a 3.4% premium).
    • The value of the conversion option implies an effective cost of 13.52%, an attractive financing rate given the use of proceeds and our assessment of credit quality.
    • The proceeds will pay short-term loans and obligations, preserving cash to support growth in Germany.

Week ended 05/31/2024

Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more. 

Weekly Credit Tracker

Each week, Viridian highlights a specific industry sector and provides a deep dive into credit metrics and comparable company credit rankings for public companies operating in that sector.  Credit ratings are not currently available for public cannabis companies leaving companies, lenders, and investors with a gap of information. The Viridian Cannabis Credit Tracker fills this gap. The model uses 11 market and financial statement variables to discern 4 key credit factors: Liquidity, Leverage, Profitability, and Size, to provide credit/liquidity analysis for over 370 public Cannabis/Hemp companies.

This week’s credit tracker focuses on the 7 Canadian Cultivation & Retail sector companies with market caps between $50M and $500M in the Viridian Value Tracker database in order to make the case that Auxly had a good reason to sell assets, even at prices significantly below its cost:  The firm is over levered and needs to sell assets to reduce debt.  The Viridian Credit tracker ranking system shows Auxly near the bottom of the peer group in terms of credit quality. 

This Chart is Only Available to Higher Tier Memberships

Please Purchase a Premium or Enterprise membership to see more.

Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more. 

This Chart is Only Available to Higher Tier Memberships

Please Purchase a Premium or Enterprise membership to see more.